Trial reportDrug design, development and therapy2025
Low-Dose Dexmedetomidine Attenuates the Dose Requirement of Propofol for Suppression of Body Movement in Patients Undergoing Operative Hysteroscopy.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Low-Dose Dexmedetomidine Reduces Median Effective Doses of Propofol Required for Successful Gastroscope Insertion: A Prospective Randomized Controlled Dose-Finding Trial.Therapeutics and clinical risk management · 2026Trial
- Effect of Different Doses of Esketamine on the Propofol Effect-Site Concentration Required to Suppress Cervical Dilation-Associated Movement During Hysteroscopy: A Prospective, Randomised, Controlled, Parallel-Group Dose-Response Trial.Drug design, development and therapy · 2026Trial
- The Optimal Doses of Dexmedetomidine Combined with Propofol in Patients in Hysteroscopic Surgery: A Randomized Controlled Trial.Drug design, development and therapy · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dexmedetomidine is a central α-2 adrenergic agonist characterized by its sedative, analgesic, and sympatholytic properties. We investigated the effect of low dose dexmedetomidine on the dose-response relationship of propofol for sedation in patients undergoing operative hysteroscopy. Methods: The patients were firstly randomly assigned to receive either propofol and fentanyl (P group, n = 100) or a combination of propofol, dexmedetomidine, and fentanyl (DP group, n = 100). Subsequently, participants were further randomized to receive propofol at doses of 1.0, 1.5, 2.0, and 2.5 mg/kg in P group, and 0.5, 1.0, 1.5, and 2.0 mg/kg in DP group. The primary outcome of this study was the incidence of patients achieving effective propofol dose, defined as the dosage at which a patient exhibited no body movement during cervical dilation and had a BIS value below60. The Probit method was used to calculate the ED50 and ED95 of propofol in the inhibition of body movement reaction to cervical dilation during hysteroscopic surgery. Results: The ED50 and ED95 values for propofol in the inhibition of body movement reaction to cervical dilation during hysteroscopic surgery were 1.781 (95% CI 1.507~2.118) and 4.670 (95% CI 3.555~7.506) mg/kg, respectively, in P group; while in the DP group, these values were found to be 0.983 (95% CI 0.800~1.173) and 2.578 (95% CI 2.013~3.895) mg/kg. Conclusion: Low-dose dexmedetomidine (0.5μg/kg) could reduce the requirement of propofol for suppression of body movement in patients undergoing operative hysteroscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.